Capital Return Plan Follows Interim Results

NIOX Group Plc (LSE:NIOX), the maker of devices for measuring airway inflammation, published its interim results on 29 September 2026 and, on the same morning, announced a proposed tender offer together with notice of a general meeting. The move follows the board's statement in a 28 July 2026 trading update that it intended to return excess capital to shareholders during the second half of the year, with the mechanism to be confirmed alongside the interims. Detailed terms of the tender offer are set out in the company's circular.

What the Company Does

NIOX develops and sells point-of-care devices that measure fractional exhaled nitric oxide, a marker of type 2 airway inflammation used in the diagnosis and management of asthma. Its products are used by clinicians in primary and specialist care, and the company also earns trial-related revenue from pharmaceutical groups that use its technology in clinical trials. Jonathan Emms is chief executive.

Latest Developments

According to the July trading update, revenue for the six months to 30 June 2026 was approximately £24.0m, compared with £25.2m in the first half of 2025. Clinical revenue rose to about £20.6m from £20.0m, while trial-related revenue fell to around £3.4m from £5.2m. The company attributed the decline in trial-related income to a return to more normal clinical trial activity after an unusually solid 2025.

Product development has also progressed. The next-generation NIOX PRO device has received CE Mark and UK MHRA approval, and the company said it expected approvals in the United States and Japan during the second half of 2026. These markets are significant for the group's longer-term growth ambitions.

Financial and Dividend Picture

Adjusted EBITDA for the first half was about £8.3m, compared with £9.2m a year earlier, while gross margin improved slightly to about 71%. Operating expenditure was broadly stable at around £8.8m. Net cash stood at about £16.8m at the end of June, down from £19.9m at 31 December 2025 after the payment of a £6.5m final dividend.

The company said trading was in line with market consensus, which it cited as revenue of £50.5m and adjusted EBITDA of £17.5m for 2026, and that it expected the second half to be firmer than the first. Mr Emms said the group remained confident of delivering full-year performance in line with market expectations. The proposed tender offer represents an additional route for returning cash beyond ordinary dividends.

Sector and Index Context

NIOX is one of the more profitable healthcare technology companies within the FTSE AIM All Share Index, where many medical device businesses remain loss-making. Its combination of recurring consumable sales, positive cash generation and shareholder distributions sets it apart from many earlier-stage peers that still depend on external funding.

Key Risks

Trial-related revenue depends on the timing of pharmaceutical trials and can be volatile. Regulatory approval timelines for NIOX PRO in the United States and Japan are not assured, and delays could affect growth expectations. Reimbursement policy changes, competition from alternative diagnostic methods and currency movements could also weigh on performance. The tender offer requires shareholder approval at the general meeting.

What to Watch Next

Key near-term events include the outcome of the general meeting on the tender offer, regulatory decisions on NIOX PRO in the United States and Japan, and a full-year trading update, which in 2026 the company published in January. Whether second-half revenue delivers the expected uplift will be closely followed.